Fiche centre
Fred Hutch/University of Washington Cancer Consortium
Seattle — United States
Essais liés5clinical trials
VilleSeattlelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02483000
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Rituximab | SEP | Phase 2 | NCT07731789 | Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma | RECRUITING |
| Allogeneic Hematopoietic Stem Cell Transplantation | SEP | Phase 2 | NCT00104858 | Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | COMPLETED |
| Bone marrow biopsy | Cancer | Phase 1/2 | NCT05455697 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING |
| Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein | SEP | Phase 1 | NCT02483000 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies | TERMINATED |
| Anti-Thymocyte Globulin | Myasthénie | Phase 2 | NCT00716066 | Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases | ACTIVE_NOT_RECRUITING |